Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer
BackgroundThe spatial distribution of tumor-infiltrating T cells and its dynamics during chemoradiotherapy combined with PD-1 blockade is little known in esophageal squamous cell carcinoma (ESCC).MethodsWe applied the multiplex immunofluorescence method to identify T cells (CD4+, CD8+ T cells, and t...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1138054/full |
| _version_ | 1797823623372734464 |
|---|---|
| author | Cihui Yan Hui Huang Zhunhao Zheng Xiaoxue Ma Gang Zhao Tian Zhang Xi Chen Fuliang Cao Hui Wei Jie Dong Peng Tang Hongjing Jiang Meng Wang Ping Wang Qingsong Pang Wencheng Zhang |
| author_facet | Cihui Yan Hui Huang Zhunhao Zheng Xiaoxue Ma Gang Zhao Tian Zhang Xi Chen Fuliang Cao Hui Wei Jie Dong Peng Tang Hongjing Jiang Meng Wang Ping Wang Qingsong Pang Wencheng Zhang |
| author_sort | Cihui Yan |
| collection | DOAJ |
| description | BackgroundThe spatial distribution of tumor-infiltrating T cells and its dynamics during chemoradiotherapy combined with PD-1 blockade is little known in esophageal squamous cell carcinoma (ESCC).MethodsWe applied the multiplex immunofluorescence method to identify T cells (CD4+, CD8+ T cells, and their PD-1− or PD-1+ subsets) and myeloid-derived cells (CD11c+ dendritic cells, CD68+ macrophages, and their PD-L1+ subpopulations) in paired tumor biopsies (n = 36) collected at baseline and during combination (40 Gy of radiation) from a phase Ib trial (NCT03671265) of ESCC patients treated with first-line chemoradiotherapy plus anti-PD-1 antibody camrelizumab. We used the FoundationOne CDx assay to evaluate tumor mutational burden (TMB) in baseline tumor biopsies (n = 14). We dynamically assessed the nearest distance and proximity of T-cell subsets to tumor cells under combination and estimated the association between T-cell spatial distribution and combination outcome, myeloid-derived subsets, TMB, and patient baseline characteristics.FindingsWe found that the tumor compartment had lower T-cell subsets than the stromal compartment but maintained a comparable level under combination. Both before and under combination, PD-1− T cells were located closer than PD-1+ T cells to tumor cells; T cells, dendritic cells, and macrophages showed the highest accumulation in the 5–10-μm distance. Higher CD4+ T cells in the tumor compartment and a shorter nearest distance of T-cell subsets at baseline predicted poor OS. Higher baseline CD4+ T cells, dendritic cells, and macrophages were associated with worse OS in less than 10-μm distance to tumor cells, but related with better OS in the farther distance. Higher on-treatment PD-1-positive-expressed CD4+ and CD8+ T cells within the 100-μm distance to tumor cells predicted longer OS. T cells, dendritic cells, and macrophages showed a positive spatial correlation. Both high TMB and smoking history were associated with a closer location of T cells to tumor cells at baseline.ConclusionsWe firstly illustrated the T-cell spatial distribution in ESCC. Combining chemoradiotherapy with PD-1 blockade could improve the antitumor immune microenvironment, which benefits the treatment outcome. Further understanding the precision spatiality of tumor-infiltrating T cells would provide new evidence for the tumor immune microenvironment and for the combination treatment with immunotherapy. |
| first_indexed | 2024-03-13T10:26:38Z |
| format | Article |
| id | doaj.art-396e8e8dc95b453987ffb7adba703b06 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T10:26:38Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-396e8e8dc95b453987ffb7adba703b062023-05-19T05:37:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11380541138054Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancerCihui Yan0Hui Huang1Zhunhao Zheng2Xiaoxue Ma3Gang Zhao4Tian Zhang5Xi Chen6Fuliang Cao7Hui Wei8Jie Dong9Peng Tang10Hongjing Jiang11Meng Wang12Ping Wang13Qingsong Pang14Wencheng Zhang15Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Endoscopy Diagnosis and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Nutrition Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaBackgroundThe spatial distribution of tumor-infiltrating T cells and its dynamics during chemoradiotherapy combined with PD-1 blockade is little known in esophageal squamous cell carcinoma (ESCC).MethodsWe applied the multiplex immunofluorescence method to identify T cells (CD4+, CD8+ T cells, and their PD-1− or PD-1+ subsets) and myeloid-derived cells (CD11c+ dendritic cells, CD68+ macrophages, and their PD-L1+ subpopulations) in paired tumor biopsies (n = 36) collected at baseline and during combination (40 Gy of radiation) from a phase Ib trial (NCT03671265) of ESCC patients treated with first-line chemoradiotherapy plus anti-PD-1 antibody camrelizumab. We used the FoundationOne CDx assay to evaluate tumor mutational burden (TMB) in baseline tumor biopsies (n = 14). We dynamically assessed the nearest distance and proximity of T-cell subsets to tumor cells under combination and estimated the association between T-cell spatial distribution and combination outcome, myeloid-derived subsets, TMB, and patient baseline characteristics.FindingsWe found that the tumor compartment had lower T-cell subsets than the stromal compartment but maintained a comparable level under combination. Both before and under combination, PD-1− T cells were located closer than PD-1+ T cells to tumor cells; T cells, dendritic cells, and macrophages showed the highest accumulation in the 5–10-μm distance. Higher CD4+ T cells in the tumor compartment and a shorter nearest distance of T-cell subsets at baseline predicted poor OS. Higher baseline CD4+ T cells, dendritic cells, and macrophages were associated with worse OS in less than 10-μm distance to tumor cells, but related with better OS in the farther distance. Higher on-treatment PD-1-positive-expressed CD4+ and CD8+ T cells within the 100-μm distance to tumor cells predicted longer OS. T cells, dendritic cells, and macrophages showed a positive spatial correlation. Both high TMB and smoking history were associated with a closer location of T cells to tumor cells at baseline.ConclusionsWe firstly illustrated the T-cell spatial distribution in ESCC. Combining chemoradiotherapy with PD-1 blockade could improve the antitumor immune microenvironment, which benefits the treatment outcome. Further understanding the precision spatiality of tumor-infiltrating T cells would provide new evidence for the tumor immune microenvironment and for the combination treatment with immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1138054/fullesophageal squamous cell carcinomaspatial analysisimmunotherapychemoradiotherapyPD-1tumor-infiltrating T cell |
| spellingShingle | Cihui Yan Hui Huang Zhunhao Zheng Xiaoxue Ma Gang Zhao Tian Zhang Xi Chen Fuliang Cao Hui Wei Jie Dong Peng Tang Hongjing Jiang Meng Wang Ping Wang Qingsong Pang Wencheng Zhang Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer Frontiers in Immunology esophageal squamous cell carcinoma spatial analysis immunotherapy chemoradiotherapy PD-1 tumor-infiltrating T cell |
| title | Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer |
| title_full | Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer |
| title_fullStr | Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer |
| title_full_unstemmed | Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer |
| title_short | Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer |
| title_sort | spatial distribution of tumor infiltrating t cells indicated immune response status under chemoradiotherapy plus pd 1 blockade in esophageal cancer |
| topic | esophageal squamous cell carcinoma spatial analysis immunotherapy chemoradiotherapy PD-1 tumor-infiltrating T cell |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1138054/full |
| work_keys_str_mv | AT cihuiyan spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT huihuang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT zhunhaozheng spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT xiaoxuema spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT gangzhao spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT tianzhang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT xichen spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT fuliangcao spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT huiwei spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT jiedong spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT pengtang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT hongjingjiang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT mengwang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT pingwang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT qingsongpang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer AT wenchengzhang spatialdistributionoftumorinfiltratingtcellsindicatedimmuneresponsestatusunderchemoradiotherapypluspd1blockadeinesophagealcancer |